A sponsor-focused guide to clinical trials in North Macedonia; covering EU accession driven regulatory development, Skopje's research ecosystem, diverse patient access, and opportunities for regional Balkan study expansion.
North Macedonia is a small but strategically interesting market for clinical trials in the Balkans. With EU accession momentum, a diverse population, developing regulatory alignment, and a concentrated medical infrastructure around Skopje, it offers sponsors a focused opportunity for regional expansion.
North Macedonia is not yet an EU member, meaning clinical trial submissions follow national rather than CTIS procedures. However, the country's legislation is substantially EU-aligned under the EU accession harmonization process, GCP standards are implemented in national law, and regional CROs including HungaroTrial and Clinres Farmacija routinely operate there as part of CEE/Balkans multi-country programmes. The country's small but growing clinical trial activity makes it a viable add-on destination for sponsors building comprehensive Balkans programmes.
The accession trajectory: North Macedonia's EU candidate status and active accession negotiations mean its regulatory framework is progressively converging with EU CTR standards. Sponsors who establish relationships with Macedonian sites now are positioning ahead of the regulatory harmonization that will follow accession; similar to how early movers in Romania and Bulgaria benefited from pre-accession relationships.
North Macedonia's 2.1 million people are ethnically diverse; approximately 64% Macedonian, 25% Albanian, with smaller Turkish, Roma, Serbian, and Bosniak communities. This ethnic diversity, while administratively complex, offers sponsors access to distinct genetic profiles rarely studied in clinical trials; the Albanian and Macedonian populations carry different genetic backgrounds from the more commonly studied Western and Central European cohorts. Treatment-naïve patient populations across cardiovascular disease, oncology, and metabolic disorders are available across the country's universal healthcare system, which is centred on the Skopje clinical complex and regional hospitals in Bitola, Ohrid, and Štip.
North Macedonia's value lies in its EU accession trajectory, diverse patient populations, and very low operating costs; making it a natural add-on for sponsors already running Serbia, Bulgaria, or Croatia programmes.
EU candidate with active accession negotiations; GCP in national law; EU pharmaceutical legislation alignment ongoing; regional CROs (HungaroTrial, Clinres) operating with established local relationships; straightforward entry through CEE CRO partnerships.
Very low trial operating costs; competitive investigator fees; compact Skopje hub enabling efficient multi-site coordination; typically included as add-on to Serbia, Bulgaria, or Croatia Balkan programmes; incremental patient access without proportional overhead.
2.1M people; ethnically diverse (Macedonian + Albanian populations with distinct genetics); treatment-naïve pools in CVD, oncology, and metabolic disease; historically low trial participation leaves large untapped potential; universal healthcare coverage providing structured access.
"Ss. Cyril and Methodius" University; Skopje medical school; University Clinic Complex in Skopje; regional hospitals in Bitola, Ohrid, and Štip; GCP-trained investigators through regional CRO capacity-building; established CEE CRO operational framework.
Cardiovascular and oncology lead North Macedonia's therapeutic mix, with endocrinology, neurology, and broader internal medicine areas providing additional opportunity.
Skopje anchors North Macedonia's clinical research through the University Clinic Complex; Bitola and Štip extend regional reach across the country's primary patient catchments.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | University Clinic for Hematology; Skopje | Skopje | "Ss. Cyril and Methodius" University affiliate; hematology and oncology trials; North Macedonia's leading hematology research centre; Phase II–IV; part of University Clinic Complex. |
| 02 | University Clinic for Oncology; Skopje | Skopje | National oncology specialist; Phase II–IV solid tumour trials; medical oncology and radiation oncology; "Ss. Cyril and Methodius" University affiliate; primary oncology research site. |
| 03 | University Clinic for Cardiology; Skopje | Skopje | National cardiovascular specialist; Phase II–IV cardiac trials; interventional cardiology and heart failure; large treatment-naïve cardiovascular patient population; University Clinic Complex. |
| 04 | General Hospital Bitola | Bitola | Southern Macedonia regional hospital; oncology, cardiovascular, and internal medicine trials; access to Bitola region patient population; Phase II–III commercial portfolio. |
| 05 | General Hospital Štip | Štip | Eastern Macedonia regional hospital; cardiovascular and metabolic disease trials; access to Eastern Macedonia patient population; Phase II–III commercial portfolio. |
| 06 | University Clinic for Neurology; Skopje | Skopje | National neurology specialist; Phase II–IV CNS and neurodegenerative disease trials; large treatment-naïve neurological patient population; "Ss. Cyril and Methodius" University affiliate. |
"Ss. Cyril and Methodius" University affiliate; hematology and oncology trials; North Macedonia's leading hematology research centre; Phase II–IV; part of University Clinic Complex.
National oncology specialist; Phase II–IV solid tumour trials; medical oncology and radiation oncology; "Ss. Cyril and Methodius" University affiliate; primary oncology research site.
National cardiovascular specialist; Phase II–IV cardiac trials; interventional cardiology and heart failure; large treatment-naïve cardiovascular patient population; University Clinic Complex.
Southern Macedonia regional hospital; oncology, cardiovascular, and internal medicine trials; access to Bitola region patient population; Phase II–III commercial portfolio.
Eastern Macedonia regional hospital; cardiovascular and metabolic disease trials; access to Eastern Macedonia patient population; Phase II–III commercial portfolio.
National neurology specialist; Phase II–IV CNS and neurodegenerative disease trials; large treatment-naïve neurological patient population; "Ss. Cyril and Methodius" University affiliate.
These are the primary regulatory, academic, and industry bodies shaping North Macedonia's clinical research ecosystem.
National competent authority; EU-aligned legislation under accession process; GCP in national law; clinical trial approvals; working toward full EU CTR alignment as part of accession negotiations.
North Macedonia's leading university; medical faculty in Skopje; University Clinic Complex affiliates; drives investigator pipeline; GCP training through regional CRO partnerships.
Regional CRO with North Macedonia coverage; packages North Macedonia into Balkans multi-country programmes alongside Serbia, Croatia, and Bosnia; oncology, cardiology, rare disease; established local investigator relationships.
Ljubljana-based CRO with Southeast European coverage including North Macedonia; clinical operations and site management; GCP standards implementation; links Macedonian sites into broader Balkans programmes.
For sponsors evaluating clinical trials in North Macedonia, the opportunity is defined by the country's regulatory pathway, investigator depth, patient access, and fit within a wider regional clinical research strategy. This profile is designed to support faster country feasibility, smarter site selection, and more informed clinical trial planning through Kitsa.
North Macedonia is a frontier market for clinical research; small (2.1M people), not yet EU-accredited, but actively converging with EU regulatory standards and routinely included in Balkans multi-country programmes by regional CROs. Its value is incremental: sponsors running Serbia, Bulgaria, or Croatia programmes can add North Macedonia with minimal additional overhead through established CRO partnerships, gaining access to treatment-naïve Macedonian and Albanian patient populations at very low cost. As EU accession progresses and MALMED harmonizes further with EU CTR, North Macedonia will increasingly resemble the pre-accession Romania and Bulgaria of a decade ago; and early sponsor relationships will prove their worth.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.